Provided by Tiger Trade Technology Pte. Ltd.

Foghorn Therapeutics Inc.

2.92
-0.6500-18.21%
Post-market: 2.920.00000.00%18:53 EDT
Volume:13.37M
Turnover:30.86M
Market Cap:173.41M
PE:-3.00
High:3.21
Open:2.08
Low:1.79
Close:3.57
52wk High:7.61
52wk Low:1.79
Shares:59.39M
Float Shares:28.08M
Volume Ratio:30.71
T/O Rate:47.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9742
EPS(LYR):-1.1800
ROE:-470.38%
ROA:-19.92%
PB:-2.14
PE(LYR):-2.47

Loading ...

Foghorn Stock Craters as Lilly Scraps Cancer Deal, Forcing Nearly Half of Staff Layoffs

Dow Jones
·
Yesterday

Sector Update: Healthcare

MT Newswires Live
·
3 hours ago

Foghorn Therapeutics downgraded to Market Perform from Outperform at Citizens

TIPRANKS
·
4 hours ago

US Stocks on the MOVE-Cardinal Health, nVent, Acuity

Reuters
·
4 hours ago

Foghorn Therapeutics: Buy Rating Maintained as Strategy Refocuses on EP300 Degrader; Price Target Cut to $5 After SMARCA2 Program Removal

TIPRANKS
·
5 hours ago

Foghorn Therapeutics price target lowered to $5 from $12 at Stifel

TIPRANKS
·
5 hours ago

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Yesterday

Foghorn Therapeutics Shares Fall 45% Premarket After Co Scraps Development of Cancer Drug with Eli Lilly, to Cut 40% of Workforce

THOMSON REUTERS
·
Yesterday

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Yesterday

Foghorn Therapeutics Cuts Workforce About 40% in Reorganization to Extend Cash Runway into H2 2029

Reuters
·
Yesterday

Foghorn Therapeutics - Expects to Have About 65 Full-Time Employees After Reduction - SEC Filing

THOMSON REUTERS
·
Yesterday

Foghorn Therapeutics - Estimates $2.30 Mln Charges for Workforce Reduction in Q4 2026 - SEC Filing

THOMSON REUTERS
·
Yesterday

Foghorn Therapeutics Inc.: One-Time Employee Severance and Benefit Costs That are Expected to be Incurred in Q4 of 2026

THOMSON REUTERS
·
Yesterday

Foghorn Therapeutics: Also not be Advancing Selective Smarca2 Degrader Program, Companies Do not Anticipate Further Collaboration Activities

THOMSON REUTERS
·
Yesterday

Foghorn Therapeutics - to Focus Resources on Wholly Owned Pipeline Including Ep300 and Cbp Degraders

THOMSON REUTERS
·
Yesterday

Foghorn Therapeutics - Expects Cash Runway into Second Half of 2029 with 40% Workforce Reduction

THOMSON REUTERS
·
Yesterday

Foghorn Therapeutics Provides Update on Fhd-909 and Strategic Priorities

THOMSON REUTERS
·
Yesterday

Foghorn Therapeutics - to Reduce Workforce by About 40% and Align Operating Structure

THOMSON REUTERS
·
Yesterday

Foghorn Therapeutics - Co and Lilly Will not Advance Fhd-909 or Selective Smarca2 Degrader Program

THOMSON REUTERS
·
Yesterday

Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities

GlobeNewswire
·
Yesterday